🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share work from chris bahl! When at IPI, the team used #AI to interrogate the functional sequence landscape of #proteinbinding sites in silico to better understand #COVID evolution & mitigation. Nice job & wishing you well, AI Proteins team! ➡️ onlinelibrary.wiley.com/doi/10.1002/pr…

I'm extremely grateful to the stellar team of collaborators that made it a joy to work on this story: Mireiaa Jelena Vučinić Jared Adolf-Bryfogle James Bowman Sébastien Verel, Isabelle Moczygemba Thomas Schiex David Simoncini proudly published in proteinsociety's Protein Science

We are honored to be selected as a Falling Walls Venture winner! Our de novo designed #miniprotein therapeutics promise to be a game changer for patients, and this recognition is a testament to the hard work and dedication of our team

so excited that our field of protein design has been awarded a The Nobel Prize, and it's amazing to see my postdoc advisor receive this very well-deserved recognition!! and congrats to all of the brilliant and insightful researchers who made key contributions to these breakthroughs!

Excited to share that a de novo designed miniprotein that myself, chris bahl, and Frank created during my post-doc is now in humans! The miniprotein is a Nectin-4 binding radiopharmaceutical being developed by Aktis Oncology.

Happy Halloween!

Our founder, President and CSO Chris Bahl chris bahl went to the Falling Walls Science Summit last week to explain how we make #miniprotein therapeutics with unprecedented ability to control cellular behavior - you can check out the recording 👇 youtube.com/live/zB6-iUB9z…

We're excited that Mireia Solà Colom Mireiaa, our Head of Immunotherapeutics will share some of our latest work on immune cell engagers at Boston Protein Design and Modeling Club next month!

We've got some very exciting news to share! businesswire.com/news/home/2024… and here's a 🧵 about the journey from academia to AI Proteins

Exciting times at AI Proteins! We are getting so close to see our drugs helping patients! fiercebiotech.com/biotech/bristo…

See Mireia Solà Colom Mireiaa, Head of Immunotherapeutics at AI Proteins, as she presents our latest progress on the design and optimization of immune cell engagers built from our de novo #miniproteins

So, I might have ended up on the jumbotron at the Celtics game proudly wearing my AI Proteins colors

We're delighted to share that our #Founder Chris Bahl chris bahl is now our CEO! businesswire.com/news/home/2025…

Biotechnology firm AI Proteins has partnered with the Mizzou to advance the use of de novo designed miniproteins for targeted radioligand cancer therapy using its AI-powered platform. aibusiness.com/health-care/ai…

Welcome Phil Brandish, Chief Development Officer, to the AI Proteins team! businesswire.com/news/home/2025…

I am so grateful to be back on the TED stage this week in Vancouver to share an update on our story. In the 6 years since my last TED talk, I left academia and founded AI Proteins. I can't wait to tell you about what we've been building. businesswire.com/news/home/2025…

It was an honor to speak from the main stage at TED Talks last week about our work at AI Proteins